ResearcherShenzhen UniversityActive in the last 2 years

Lin Lin

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5137315545. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Nimotuzumab combined with gemcitabine and nab-paclitaxel as first-line therapy for advanced pancreatic cancer: a single-arm, single-center Phase II prospective… Co-author DOI 10.3389/fmed.2026.1838482 ↗
Circ_0058058 Drives the Malignant Phenotypes and Immune Evasion of Pancreatic Cancer by the MicroRNA-557-Dependent Regulation of PDL1. Co-author DOI 10.1097/mpa.0000000000002205 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shaozhong He · 1 shared paper, 2026 · strength 0.32
- Paper Nimotuzumab combined with gemcitabine and nab-paclitaxel as first-line therapy for advanced pancreatic cancer: a single… DOI 10.3389/fmed.2026.1838482 ↗
Xuehao Gong · 1 shared paper, 2022 · strength 0.16
- Paper Circ_0058058 Drives the Malignant Phenotypes and Immune Evasion of Pancreatic Cancer by the MicroRNA-557-Dependent Regu… DOI 10.1097/mpa.0000000000002205 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.